ArticleMedical oncology (Northwood, London, England)2025
In vitro assessment of anti-glioblastoma potential of Emblica officinalis methanolic fruit extract and green nanoparticles in U87-MG cells.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPlant-derived and other natural products are gaining attention due to wide therapeutic properties, specifically being looked for development of alternative therapeutic intervention for cancers. Phyllanthus emblica, also called Emblica officinalis, is well known for its abundance of phytochemicals and therapeutic uses since ancient times, and reports suggest its anticancer properties. However, no studies are conducted for brain cancers.
aimThe current study aims to evaluate the anti-brain cancer property of E. officinalis and to enhance the potency of selected extracts by development of green silver nanoparticles (AgNPs). METHODOLOGY AND
resultsThe Methanolic, Ethanolic, and Aqueous extracts of E. officinalis (M-EOE, E-EOE, and A-EOE) were obtained, followed by measuring total phenolic content and DPPH analysis. The results presented M-EOE with the highest presence of phenolic compounds, as supported by GC-MS. MTT assays showed dose-dependent antiproliferative potential of these extracts against U87-MG, where methanolic extract exhibited the lowest IC
conclusionThe current study thus suggests that E. officinalis extracts and derived nanoparticles may have the potential to be exploited as anti-brain cancer therapeutics and should be evaluated further by detailed mechanistic studies.
Indexed as
Identifiers
41085866What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.